Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK -Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

• Published in: Cancers 2022-12, Vol.15 (1), p.204
• Main Authors: Watanabe, Satoshi, Sakai, Kazuko, Matsumoto, Naoya, Koshio, Jun, Ishida, Akira, Abe, Tetsuya, Ishikawa, Daisuke, Tanaka, Tomohiro, Aoki, Ami, Kajiwara, Tomosue, Koyama, Kenichi, Miura, Satoru, Goto, Yuka, Sekiya, Tomoki, Suzuki, Ryo, Kushiro, Kohei, Fujisaki, Toshiya, Yanagimura, Naohiro, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Saida, Yu, Yoshizawa, Hirohisa, Nishio, Kazuto, Kikuchi, Toshiaki
• Format: Article
• Language: English
• Subjects: Angiogenesis; Bevacizumab; Biomarkers; c-Met protein; Cancer therapies; Enzyme inhibitors; Epidermal growth factor; Fusion protein; Genes; Hypotheses; Kinases; Lung cancer; Mutation; Non-small cell lung carcinoma; Patients; Plasma; Plasma proteins; Protein-tyrosine kinase; Proteins; Small cell lung carcinoma; Statistical analysis; Toxicity; Tumors; Vascular endothelial growth factor
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15010204

Anaplastic lymphoma kinase ( )-positive lung cancer is a rare cancer that occurs in approximately 5% of non-small-cell lung cancer (NSCLCs) patients. Despite the excellent efficacy of ALK-tyrosine kinase inhibitor in -positive NSCLCs, most patients experience resistance. We conducted a phase II study to investigate the combination of alectinib with bevacizumab in -positive NSCLC patients after failure of alectinib. In this study, -positive nonsquamous NSCLC patients previously treated with alectinib received bevacizumab 15 mg/kg on day 1 every 3 weeks and alectinib 600 mg/day until disease progression. The primary endpoints were progression-free survival (PFS) and the safety of alectinib and bevacizumab. The secondary endpoints included overall survival (OS) and correlation of circulating tumor DNA and plasma proteins with PFS. Of the 12 patients treated, the median PFS was 3.1 months (95% CI 1.2-16.1), and the median OS was 24.1 months (95% CI 8.3-not estimable). The fusion gene in circulating tumor DNA was significantly correlated with shorter PFS (1.2 months vs. 11.4 months, HR 5.2, = 0.0153). Two patients experienced grade 3 adverse events; however, none of the patients required dose reduction. Although the primary endpoint was not met, alectinib combined with bevacizumab showed clinical efficacy in -positive patients.